Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone858-794-8889
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$151.86 million
Profitability
Miscellaneous
Employees281
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions
What is Halozyme Therapeutics' stock symbol?
Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."
How were Halozyme Therapeutics' earnings last quarter?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its earnings results on Tuesday, May, 7th. The biopharmaceutical company reported $0.01 EPS for the quarter, meeting analysts' consensus estimates of $0.01. The biopharmaceutical company had revenue of $56.95 million for the quarter, compared to analysts' expectations of $67.80 million. Halozyme Therapeutics had a negative return on equity of 20.36% and a negative net margin of 28.70%. The company's quarterly revenue was up 84.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.19) earnings per share. View Halozyme Therapeutics' Earnings History.
When is Halozyme Therapeutics' next earnings date?
What guidance has Halozyme Therapeutics issued on next quarter's earnings?
Halozyme Therapeutics updated its FY 2019 earnings guidance on Tuesday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $205-215 million, compared to the consensus revenue estimate of $209.09 million.
What price target have analysts set for HALO?
4 equities research analysts have issued 1-year price objectives for Halozyme Therapeutics' shares. Their predictions range from $17.00 to $24.00. On average, they expect Halozyme Therapeutics' share price to reach $20.75 in the next twelve months. This suggests a possible upside of 25.7% from the stock's current price. View Analyst Price Targets for Halozyme Therapeutics.
What is the consensus analysts' recommendation for Halozyme Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Halozyme Therapeutics.
What are Wall Street analysts saying about Halozyme Therapeutics stock?
Here are some recent quotes from research analysts about Halozyme Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $24 PT per share on HALO. Halozyme reported 1Q19 revenues of $57M, which were below our and FactSet consensus estimates of $62M and $69M, respectively. Additionally, the company ended 1Q19 with cash of ~$329M, and we model current cash and projected ENHANZE royalties to fund HALO through key value-creating milestones. During 1Q19, royalty revenues declined by 14% YoY, mainly due to lower sales of Herceptin SC in Europe, which were partially offset by higher sales of RITUXAN HYCELA versus 1Q18." (5/8/2019)
- 2. According to Zacks Investment Research, "Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine. " (4/25/2019)
Has Halozyme Therapeutics been receiving favorable news coverage?
Press coverage about HALO stock has been trending somewhat negative on Thursday, InfoTrie reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Halozyme Therapeutics earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Halozyme Therapeutics.
Are investors shorting Halozyme Therapeutics?
Halozyme Therapeutics saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 7,583,100 shares, an increase of 39.1% from the April 30th total of 5,450,500 shares. Based on an average trading volume of 803,300 shares, the short-interest ratio is presently 9.4 days. Currently, 5.9% of the company's shares are short sold. View Halozyme Therapeutics' Current Options Chain.
Who are some of Halozyme Therapeutics' key competitors?
Some companies that are related to Halozyme Therapeutics include Qiagen (QGEN), BIO-TECHNE (TECH), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), argenx (ARGX), Spark Therapeutics (ONCE), Ablynx (ABLYF), Repligen (RGEN), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Regenxbio (RGNX) and Denali Therapeutics (DNLI).
What other stocks do shareholders of Halozyme Therapeutics own?
Who are Halozyme Therapeutics' key executives?
Halozyme Therapeutics' management team includes the folowing people:
- Dr. Helen I. Torley, Pres, CEO & Director (Age 56)
- Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 51)
- Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel & Corp. Sec. (Age 62)
- Dr. Dimitrios Chondros, Chief Medical Officer & Sr. VP (Age 54)
- Mr. Benjamin J. Hickey, Sr. VP & Chief Commercial Officer (Age 44)
Who are Halozyme Therapeutics' major shareholders?
Halozyme Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Iridian Asset Management LLC CT (4.82%), Pictet Asset Management Ltd. (2.69%), FMR LLC (1.85%), First Eagle Investment Management LLC (1.46%), Artisan Partners Limited Partnership (1.41%) and Granite Investment Partners LLC (0.70%). View Institutional Ownership Trends for Halozyme Therapeutics.
Which institutional investors are selling Halozyme Therapeutics stock?
HALO stock was sold by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, MERIAN GLOBAL INVESTORS UK Ltd, New York State Common Retirement Fund, Kennedy Capital Management Inc., Algert Global LLC, First Quadrant L P CA, Creative Planning and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Halozyme Therapeutics.
Which institutional investors are buying Halozyme Therapeutics stock?
HALO stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Candriam Luxembourg S.C.A., Federated Investors Inc. PA, Pictet Asset Management Ltd., FMR LLC, FormulaFolio Investments LLC, Marshall Wace North America L.P. and AlphaCrest Capital Management LLC. View Insider Buying and Selling for Halozyme Therapeutics.
How do I buy shares of Halozyme Therapeutics?
Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Halozyme Therapeutics' stock price today?
One share of HALO stock can currently be purchased for approximately $16.51.
How big of a company is Halozyme Therapeutics?
Halozyme Therapeutics has a market capitalization of $2.40 billion and generates $151.86 million in revenue each year. The biopharmaceutical company earns $-80,330,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe.View Additional Information About Halozyme Therapeutics.
What is Halozyme Therapeutics' official website?
How can I contact Halozyme Therapeutics?
Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]
MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)
MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days.
